Aprilbio Co. Ltd.
AprilBio Co., Ltd. develops long-acting type biobetter and antibody biologics. The company develops antibody drugs, double antibodies, long-acting antibody drugs, long-acting protein drugs, and ADC-applied antibodies. It is developing various products for use in the treatment of rare diseases, cancer, male infertility, autoimmune and inflammatory diseases. The company was founded in 2013 and is h… Read more
Aprilbio Co. Ltd. (397030) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.023x
Based on the latest financial reports, Aprilbio Co. Ltd. (397030) has a cash flow conversion efficiency ratio of -0.023x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.09 Billion) by net assets (₩90.41 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aprilbio Co. Ltd. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Aprilbio Co. Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Aprilbio Co. Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aprilbio Co. Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Newway Photomask Making Co. Ltd. A
SHG:688401
|
N/A |
|
Xiamen Anne Corp Ltd
SHE:002235
|
0.009x |
|
Zhejiang Construction Investment Group Co Ltd
SHE:002761
|
0.044x |
|
Sumitomo Osaka Cement Co. Ltd
F:SU2
|
N/A |
|
Almirall S.A
PINK:LBTSF
|
0.021x |
|
Hangzhou Steam Turbine
SHE:200771
|
0.014x |
|
Equitas Small Finance Bank Limited
NSE:EQUITASBNK
|
0.013x |
|
Wereldhave N.V
PINK:WRDEF
|
0.041x |
Annual Cash Flow Conversion Efficiency for Aprilbio Co. Ltd. (2020–2024)
The table below shows the annual cash flow conversion efficiency of Aprilbio Co. Ltd. from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩90.99 Billion | ₩21.96 Billion | 0.241x | +238.56% |
| 2023-12-31 | ₩57.75 Billion | ₩-10.06 Billion | -0.174x | -79.70% |
| 2022-12-31 | ₩69.16 Billion | ₩-6.70 Billion | -0.097x | -270.41% |
| 2021-12-31 | ₩57.17 Billion | ₩3.25 Billion | 0.057x | -89.31% |
| 2020-12-31 | ₩-13.78 Billion | ₩-7.33 Billion | 0.532x | -- |